Black Box Appears Unlikely For Singulair Ahead Of US FDA Panel Review Of Pediatric Safety
Executive Summary
US FDA seeking recommendations on further labeling and communication strategies for Merck's Singulair, which has long carried a risk of neuropsychiatric events, from the agency's Pediatric Advisory Committee and Drug Safety and Risk Management Advisory Committee.
You may also be interested in...
Singulair’s Psychiatric AE Risks Still A Problem, But US FDA Has Limited Mitigation Options Remaining
Stakeholders suggested a ‘Dear Healthcare Provider’ letter or speaking about the risks to professional societies to emphasize the psychiatric adverse events that prompted a boxed warning for the now-generic asthma drug montelukast. The NY Attorney General is adding more pressure.
US FDA Orders Singulair Boxed Warning On Neuropsychiatric Events Despite ‘Limited’ Evidence
Therapeutic alternatives and lack of prescriber and parent knowledge about existing warnings drove agency’s decision, despite internal concerns about the adequacy of the evidence to support the safety action.
Safety Communications: US FDA Panel Offers Menu Of Options For Singulair's Risks
A common theme among the public speakers at the advisory committee was that their children's prescribers never informed them of the existing warning and precaution in the label. With that in mind, the US FDA now heads to the drawing board after a joint panel offers a series of options to more effectively communicate the potential neuropsychiatric risks associated with Singulair.